Methods and applications of mouse models of intraductal papillary mucinous tumors of the pancreas and their tumor cells.
By constructing a KPPS mouse model and utilizing gene editing technology mediated by Sox9-CreER and Cre recombinase, the problems of slow tumor progression and low malignancy rate in existing IPMN mouse models were solved. This enabled efficient induction and complete presentation of pathological progression of intraductal papillary mucinous tumors of the pancreas, supporting research and drug screening.
Patent Information
- Application Number
- CN202510943806.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-09
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2045-07-09
AI Technical Summary
Existing IPMN genetically engineered mouse models suffer from long tumor progression cycles and/or low malignancy rates, failing to fully represent pathological progression.
Using the KPPS mouse model preparation method, Sox9-CreER transgenic mice, loxP-Trp53-loxP and Promoter-LSL-KrasG12D mice were constructed through hybridization and gene editing technology. The intraductal papillary mucinous tumor model of pancreas was prepared by gene knockout mediated by Cre recombinase and induction of KrasG12D mutation.
It achieves efficient induction of IPMN lesions in a short period of time, and can fully present the pathological progression from LG-IPMN to IPMN-IC, supporting mechanism research and drug screening.
Smart Images

Figure CN120814515B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a mouse model of intraductal papillary mucinous tumor of the pancreas and its tumor cells, as well as their application. Background Technology
[0002] Intraductal papillary mucinous neoplasm (IPMN) is one of the most common pancreatic cystic tumors and a precursor lesion for pancreatic cancer. The pathological features of IPMN include branching papillary projections and lesions lined with tumor epithelial cells that extend into the dilated pancreatic duct and express abundant intracellular and extracellular mucins that may fill the ductal lumen. Various gene mutations can be detected during the development of IPMN, including driver gene mutations such as KRAS and GNAS, as well as malignant progression mutations such as TP53 and CDKN2A. With a deeper understanding of the underlying gene mutations in tumorigenesis, researchers have developed various genetically engineered mouse models (GEMMs) that reproduce genetic events in the in vivo environment, allowing for tumor formation in a microenvironment with favorable innate immunity. KPPC (KPPC) Kras LSL-G12D / + ;Trp53 fl / fl ;Pdx1-CreER The mouse model is widely used in various studies of pancreatic cancer, but due to the generalization of Cre expression (non-ductal specificity), it lacks specific characterization of IPMN-associated invasive cancer (IPMN-IC).
[0003] Given the specific expression of the Sox9 gene in adult mouse pancreatic ductal cells, the Sox9-CreER tool mouse can provide a genetic manipulation platform for establishing an IPMN animal model originating from ductal cells, aiding in the investigation of its carcinogenesis mechanism. Studies have shown that inducing Kras mutations alone in ductal cells is insufficient to generate IPMN. von Figura et al. specifically expressed... Kras G12D Mutation and Knockout Brg1The gene was successfully induced to produce IPMN-like precancerous lesions, but this mouse model was only tracked for 6 weeks [von Figura, G., Fukuda, A., Roy, N., Liku, ME, Morris IV, JP, Kim, GE, Russ, HA, Firpo, MA, Mulvihill, SJ, Dawson, DW, et al. (2014). The chromatin regulator Brg1 suppresses formation of intraductal papillarymucinous neoplasm and pancreatic ductal adenocarcinoma. Nat. Cell Biol. 16,255–267. https: / / doi.org / 10.1038 / ncb2916.]. Janel L. Kopp et al. specifically expressed the gene in ductal cells. Kras G12D Mutation combined with specific knockout Pten The gene also induced IPMN-like lesions, which can eventually progress to IPMN-related invasive carcinoma. However, the tumor progression cycle in this model is long, and tumors can only be observed in mice at 6-14 months of age [Kopp, JL, Dubois, CL, Schaeffer, DF, Samani, A., Taghizadeh, F., Cowan, RW, Rhim, AD, Stiles, BL, Valasek, M., and Sander, M. (2018). Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice. Gastroenterology 154, 1509-1523.e5. https: / / doi.org / 10.1053 / j.gastro.2017.12.007.]. Summary of the Invention
[0004] In view of the technical defects of existing IPMN genetically engineered mouse models, such as long tumor progression and / or low malignancy rate and / or inability to fully present pathological progression, this invention provides a method for preparing and applying intraductal papillary mucinous tumor model mice and their tumor cells.
[0005] This invention provides a method (named Method I) for constructing genetically engineered mice for preparing a model mouse of intraductal papillary mucinous tumor of the pancreas, characterized in that: The genetically engineered mice used to create a model of intraductal papillary mucinous tumors of the pancreas were named KPPS mice. The method includes the following steps: hybridizing S-positive mice and K-P pure mice as parents to obtain KPPS mice; The S-positive mouse is a transgenic mouse carrying Sox9-CreER; the Sox9-CreER is a DNA molecule, which has a promoter and a Cre recombinase gene transcribed by the promoter from upstream to downstream; the promoter is a pancreatic duct cell-specific promoter; The K-P pure mice carry loxP-Trp53-loxP in both pairs of homologous chromosomes 11, and Promoter-LSL-Kras in one of their chromosomes 6. G12D ; The loxP-Trp53-loxP is obtained by modifying the Trp53 gene located on chromosome 11. The modification refers to inserting two loxP sites in the Trp53 gene with the same orientation, but at different insertion positions. The loxP site recombination in the loxP-Trp53-loxP results in the knockout of the Trp53 gene. The loxP site recombination is mediated by the Cre recombinase. The Promoter-LSL-Kras G12D It is obtained by modifying the region from the promoter of the Kras gene on chromosome 6 to the end of the Kras gene; the Promoter-LSL-Kras G12D From upstream to downstream, the sequence consists of the Kras gene promoter, LSL sequence, and Kras gene promoter. G12D Mutant gene; LSL sequence is a DNA fragment with two loxP sites in the same orientation and a termination box located between the two loxP sites; Kras G12D The expression of the mutant gene was blocked by the LSL sequence; the Promoter-LSL-Kras G12D Recombination at the loxP site leads to the expression of Kras, which is blocked by the LSL sequence. G12DThe mutant gene is restored to expression; the recombination at the loxP site is mediated by the Cre recombinase. The KPPS mice are S-positive, K-hybrid, and P-pure mice; S-positive, K-hybrid, and P-pure mice mean that they carry the Sox9-CreER, and both pairs of homologous chromosomes 11 carry the loxP-Trp53-loxP, and one chromosome 6 carries the Promoter-LSL-Kras. G12D .
[0006] As an example, method I includes the following steps: ① Crossing S-positive mice and K-hybrid P-pure mice as parents yields offspring mice, from which S-positive K-hybrid P-pure mice are selected; ② The male mice with S-positive K-mixed P hybrids obtained in step ① were mated with the female mice with S-positive K-mixed P hybrids obtained in step ① to obtain offspring mice. S-positive K-mixed P pure mice were then selected from the offspring mice.
[0007] The meaning of S-positive, K-positive, and P-positive is: carrying the Sox9-CreER, with one chromosome 11 carrying the loxP-Trp53-loxP, and one chromosome 6 carrying the Promoter-LSL-Kras. G12D .
[0008] As an example, method I further includes the following step ③: mating the S-positive, K-positive, P-pure male mice obtained in step ② with the S-positive, K-positive, P-pure female mice obtained in step ② to obtain offspring mice, and screening S-positive, K-positive, P-pure mice from the offspring mice.
[0009] As an example, method I further includes the following step ③: the S-positive K-hybrid P-hybrid mice obtained in step ① are mated with K-hybrid P-pure mice (e.g., commercially available mice) to obtain offspring mice, and S-positive K-hybrid P-pure mice are selected from the offspring mice.
[0010] As an example, method I further includes the following step ③: mating the S-positive K-hybrid P-hybrid mice obtained in step ① with S-negative K-hybrid P-pure mice to obtain offspring mice, and screening S-positive K-hybrid P-pure mice from the offspring mice.
[0011] The meaning of "S-negative K-mixed P pure" is: both pairs of homologous chromosomes 11 carry the loxP-Trp53-loxP, and one chromosome 6 carries the Promoter-LSL-Kras. G12D And it does not carry the Sox9-CreER.
[0012] As an example, the S-negative K-hybrid P-pure mice can be obtained by screening offspring mice from crosses between S-positive mice (e.g., commercially available mice) and K-hybrid P-pure mice (e.g., commercially available mice) as parents.
[0013] As an example, the S-negative K-hybrid P-pure mice can be obtained by screening offspring mice from the mating of male S-positive K-hybrid P-pure mice obtained in step ① and female S-positive K-hybrid P-pure mice obtained in step ①.
[0014] In some specific embodiments of the present invention, the method for identifying K-mixed products is as follows: using total mouse DNA as a template, PCR amplification is performed using a primer set (composed of primers shown in SEQ ID NO: 1, primers shown in SEQ ID NO: 2 and primers shown in SEQ ID NO: 3). If two amplification products of 100bp and 250bp are obtained, they are determined to be K-mixed.
[0015] In some specific embodiments of the present invention, the method for identifying K-negative is as follows: using total mouse DNA as a template, PCR amplification is performed using a primer set (composed of primers shown in SEQ ID NO: 1, primers shown in SEQ ID NO: 2 and primers shown in SEQ ID NO: 3). If a 250bp amplification product is obtained and no 100bp amplification product is obtained, it is determined to be K-negative.
[0016] In some specific embodiments of the present invention, the method for identifying P-purity is as follows: using total mouse DNA as a template, PCR amplification is performed using primer pairs (composed of primers shown in SEQ ID NO: 4 and primers shown in SEQ ID NO: 5). If an amplification product of 300bp-400bp is obtained and no amplification product of 270bp is obtained, it is judged to be P-purity.
[0017] In some specific embodiments of the present invention, the method for identifying P-impurities is as follows: using total mouse DNA as a template, PCR amplification is performed using primer pairs (composed of primers shown in SEQ ID NO: 4 and primers shown in SEQ ID NO: 5). If 300bp-400bp amplification products and 270bp amplification products are obtained, it is determined to be a P-impurity.
[0018] In some specific embodiments of the present invention, the method for identifying S-positive is as follows: using total mouse DNA as a template, PCR amplification is performed using primer pair A (composed of primers shown in SEQ ID NO: 6 and SEQ ID NO: 7) and primer pair B (composed of primers shown in SEQ ID NO: 8 and SEQ ID NO: 9). If a 290bp-310bp amplification product is obtained using primer pair A and a 521bp amplification product is obtained using primer pair B, it is determined to be S-positive.
[0019] In some specific embodiments of the present invention, the method for identifying S-negative is as follows: using total mouse DNA as a template, PCR amplification is performed using primer pair A (composed of primers shown in SEQ ID NO: 6 and SEQ ID NO: 7) and primer pair B (composed of primers shown in SEQ ID NO: 8 and SEQ ID NO: 9), respectively. If primer pair A does not yield a 290bp-310bp amplification product and primer pair B yields a 521bp amplification product, it is determined to be S-negative.
[0020] As an example, the Cre recombinase is an inducible Cre recombinase.
[0021] As an example, the inducible Cre recombinase is tamoxifen-induced Cre recombinase.
[0022] As an example, the tamoxifen-inducible Cre recombinase is CreER or CreERT2.
[0023] As an example, the pancreatic duct cell-specific promoter is the Sox9 gene promoter.
[0024] The Kras G12D Mutant gene expression Kras G12D Mutant protein. Compared to the protein Kras (wild-type protein), Kras... G12D The mutant protein differs only in its amino acid sequence in that the 12th amino acid residue is changed from G to D, while all other amino acid residues are the same.
[0025] As an example, the S-positive mouse is a Sox9-cre / ERT2 mouse (Sox9CreERT2). T2 ).
[0026] As an example, the S-positive mouse is the Jackson laboratory mouse number 018829.
[0027] As an example, the K-P pure mice are KP mice (LSL-K-ras G12D; p53). LoxP ).
[0028] As an example, the K-hybrid P-pure mouse is the Jackson laboratory mouse number 032435.
[0029] This invention also provides a method for preparing a mouse model of intraductal papillary mucinous tumor of the pancreas (named Method II), comprising the following steps: (1) KPPS mice were constructed according to method I described above; (2) The KPPS mice were induced by an inducer to obtain a model mouse of intraductal papillary mucinous tumor of the pancreas.
[0030] In step (2), the induction period is 6 days.
[0031] As an example, the inducer is tamoxifen.
[0032] As an example, the induction method is as follows: administer tamoxifen solution once a day for 6 consecutive days (the dosage of tamoxifen is 100 mg / kg body weight).
[0033] As an example, the induction method is as follows: administer tamoxifen solution intraperitoneally once a day for 6 consecutive days (the dosage of tamoxifen is 100 mg / kg body weight).
[0034] Tamoxifen solution: Dissolve tamoxifen in corn oil to a concentration of 10 mg / mL.
[0035] The disease course in the mouse model of intraductal papillary mucinous tumor of the pancreas lasted up to 24 weeks.
[0036] The day of the last administration is designated as day 0. In step (2), after day 28 (inclusive), a mouse model of intraductal papillary mucinous tumor of the pancreas in the IPMN stage is obtained. In some specific embodiments of the present invention, in step (2), "after day 28" refers to day 28 (inclusive) to day 168 (inclusive). In some specific embodiments of the present invention, in step (2), from day 28 to day 112, a mouse model of intraductal papillary mucinous tumor of the pancreas in the LG-IPMN stage is obtained. In some specific embodiments of the present invention, in step (2), from day 112 to day 140, a mouse model of intraductal papillary mucinous tumor of the pancreas in the HG-IPMN stage is obtained. In some specific embodiments of the present invention, in step (2), from day 84 to day 168, a mouse model of intraductal papillary mucinous tumor of the pancreas in the IPMN-IC stage is obtained.
[0037] In step (2), starting from week 4 after the induction timer is completed, mice with intraductal papillary mucinous tumors (IPMN) in the pancreatic ductal papillary mucinous tumor (IPMN) stage are obtained. In some embodiments of the present invention, starting from week 4 after the induction timer is completed refers to week 4-24. In some embodiments of the present invention, starting from week 4-16 after the induction timer is completed, mice with intraductal papillary mucinous tumors (IPMN) in the pancreatic ductal papillary mucinous tumor (IPMN) stage are obtained. In some embodiments of the present invention, starting from week 16-20 after the induction timer is completed, mice with intraductal papillary mucinous tumors (IPMN) in the pancreatic ductal papillary mucinous tumor (IPMN) stage are obtained. In some embodiments of the present invention, starting from week 12-24 after the induction timer is completed, mice with intraductal papillary mucinous tumors (IPMN) in the pancreatic ductal papillary mucinous tumor (IPMN) stage are obtained.
[0038] This invention also protects the application of KPPS mice prepared by the above-described method; the application is to prepare a mouse model of intraductal papillary mucinous tumor of the pancreas.
[0039] This invention also protects the application of the mouse model of intraductal papillary mucinous tumor of the pancreas prepared by the above-described method; the application is as follows (a) or (b) or (c): (a) Presenting the pathological progression during the progression of IPMN; (b) To conduct mechanistic studies on the progress of IPMN; (c) Conduct drug screening during the progress of IPMN.
[0040] The IPMN progress process refers to the progression of IPMN from the LG-IPMN stage to the HG-IPMN stage to the IPMN-IC stage.
[0041] The present invention also provides a tumor cell (named KPPS cell or KPPS cell line), which is a tumor cell from a mouse model of intraductal papillary mucinous tumor of pancreas obtained by any of the methods II described above.
[0042] In one specific embodiment of the present invention, the intraductal papillary mucinous tumor model mouse is a mouse in the IPMN-IC stage.
[0043] The tumor cells were isolated from pancreatic tumor tissue in mice with the intraductal papillary mucinous tumor model of pancreatic tumor.
[0044] The present invention also provides tissues or organs, characterized in that: the tissues or organs are derived from tumors in mouse models of intraductal papillary mucinous tumors of the pancreas prepared by any of the methods described above.
[0045] In China, the tissues or organs mentioned do not include embryos.
[0046] The present invention also provides a tissue or organ, characterized in that: the tissue or organ is derived from a tumor of a tumor-bearing mouse; the tumor-bearing mouse is a mouse in which the tumor cells were inoculated into a starting mouse and a tumor developed.
[0047] The starting mouse may be a mouse that does not contain the tumor cells.
[0048] As an example, the starting mouse is a C57BL / 6J mouse.
[0049] Specifically, the method for preparing the tumor-bearing mice is as follows: KPPS cells are injected into C57BL / 6J mice at a dose of 5 × 10⁻⁶. 6 Cell / animal
[0050] Specifically, the method for preparing the tumor-bearing mice is as follows: KPPS cells are subcutaneously injected into the unilateral scapular region of 8-week-old C57BL / 6J mice, with each mouse receiving 5 × 10⁶ cells. 6 Each cell.
[0051] This invention contributes to the study of the mechanisms of IPMN progression, drug screening, and the development of treatment strategies. Attached Figure Description
[0052] Figure 1 Examples of slices for LG-IPMN, HG-IPMN, and IPMN-IC.
[0053] Figure 2 This is the survival curve.
[0054] Figure 3 An exemplary photograph of immunofluorescence staining. Detailed Implementation
[0055] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.
[0056] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following examples are commercially available. Unless otherwise specified, all quantitative experiments in the following examples were performed in triplicate, and the results were averaged. All animal experiments complied with the relevant regulations of the Animal Ethics Committee of Beijing Vitaton Biotechnology Co., Ltd. (Ethics Approval Number: VST-SY-20210108). Primers were all single-stranded DNA molecules. Tamoxifen: CAS Registry Number 10540-29-1.
[0057] Tamoxifen solution: Dissolve tamoxifen in corn oil to a concentration of 10 mg / mL.
[0058] IPMN: Intraductal papillary mucinous neoplasm of the pancreas. IPMN is a precancerous lesion characterized by ductal dilation, mucus secretion, and papillary projections. IPMN is a lesion with dendritic papillary projections composed of neoplastic epithelial cells that extend into the dilated pancreatic duct and exhibit abundant intracellular and extracellular mucus, which may fill the lumen.
[0059] IPMN-IC: IPMN-associated invasive carcinoma. IPMN-IC is an invasive carcinoma that has progressed from IPMN to invade below the basement membrane. Characteristics of IPMN-IC include: small glands with abnormal structures visible in the duct walls, distorted glandular structure, and an increased nuclear-cytoplasmic ratio.
[0060] LG-IPMN: Low-grade IPMN. LG-IPMN is an early, benign stage of IPMN. Characteristics of LG-IPMN: branching papillary structures within the pancreatic ducts, covered with mild atypical epithelial cells, accompanied by intracellular / extracellular mucus accumulation.
[0061] HG-IPMN: High-grade IPMN. Compared to LG-IPMN, HG-IPMN is more malignant and has a high probability of developing into invasive carcinoma. Characteristics of HG-IPMN: more and more complex papillary structures, significant cellular atypia, increased mitotic figures, increased nuclear-cytoplasmic ratio, loss of nuclear polarity, and no signs of invasive carcinoma.
[0062] GEMMs: Genetically engineered mouse models. GEMMs mimic the genetic characteristics of human diseases using gene editing technology.
[0063] KP mice (LSL-K-ras G12D; p53) LoxP ): Jackson Laboratory, serial number 032435; KP mice are K-mixed P-pure mice. Sox9-cre / ERT2 mice (Sox9CreERT2) T2 ): Jackson Laboratory, mouse number 018829; Sox9-cre / ERT2 mice are S-positive mice. KPPC mice, also known as KPC mice (Kras) LSL-G12D p53 LoxP (Pdx1-CreER): Jackson Laboratory, number 032429; KPPC mice are genetically engineered mice with the KrasLSL-G12D;p53LoxP;Pdx1-CreER triple mutation, which were induced by tamoxifen to form a pancreatic ductal adenocarcinoma model.
[0064] Example 1: Preparation of KPPS mice I. Preparation and screening of S-positive, K-positive, and P-positive mice KP mice and Sox9-cre / ERT2 mice were mated together in four cages (one female and one male per cage, one KP mouse and the other a Sox9-cre / ERT2 mouse) to produce offspring. Approximately one-quarter of the offspring were S-positive, K-mixed, and P-mixed. S-positive, K-mixed, and P-mixed mice were then selected from the offspring.
[0065] In the above steps, the female mice gave birth every 4-6 weeks, and produced multiple offspring mice, resulting in a total of 82 offspring mice. From these offspring, 20 mice were selected as S-positive, K-positive, and P-positive.
[0066] II. Preparation and screening of S-positive, K-positive, and P-pure mice Male mice with S-positive, K-mixed, and P-mixed traits obtained in Step 1 were mated together with female mice with the same traits in Step 1 (six cages in total; one female and one male per cage) to obtain offspring mice. Approximately 3 / 32 of the offspring mice were S-positive, K-mixed, and P-pure. S-positive, K-mixed, and P-pure mice were selected from the offspring. Approximately 1 / 32 of the offspring mice were S-negative, K-mixed, and P-pure; these S-negative, K-mixed, and P-pure mice were used in Step 4. Approximately 3 / 32 of the offspring mice were S-positive, K-negative, and P-pure; these S-positive, K-negative, and P-pure mice were used in Step 6. Approximately 3 / 16 of the offspring mice were S-positive, K-mixed, and P-mixed; these S-positive, K-mixed, and P-mixed mice were used in Step 5.
[0067] In the above steps, the female mice gave birth every 4-6 weeks, and produced multiple offspring, resulting in a total of 116 offspring mice. From these offspring, 11 mice with S-positive K-positive and P-pure offspring were selected.
[0068] III. Further preparation and screening of S-positive, K-positive, and P-pure mice Male mice with S-positive, K-positive, and P-pure hybrids obtained in step two were mated together (five cages in total; one female and one male per cage) to obtain offspring. Approximately 3 / 8 of the offspring were S-positive, K-positive, and P-pure. S-positive, K-positive, and P-pure mice were then selected from the offspring. Approximately 1 / 8 of the offspring were S-negative, K-positive, and P-pure; these S-negative, K-positive, and P-pure mice were used in step four. Approximately 3 / 8 of the offspring were S-positive, K-negative, and P-pure; these S-positive, K-negative, and P-pure mice were used in step six.
[0069] In the above steps, the female mouse gives birth every 4-6 weeks, with an average of 23-25 offspring mice per month (of which 8-10 are S-positive, K-positive, and P-positive mice).
[0070] IV. Preparation of K-P-pure mice Male S-negative, K-cross hybrid, P-pure mice are mated with female S-negative, K-cross hybrid, P-pure mice to produce offspring. Approximately half of the offspring are S-negative, K-cross hybrid, P-pure mice. The parent S-negative, K-cross hybrid, P-pure mice can be KP mice, S-negative, K-cross hybrid, P-pure mice from the offspring obtained in step two, or S-negative, K-cross hybrid, P-pure mice from the offspring obtained in step three.
[0071] S-negative K-P mice can be used instead of KP mice for step one.
[0072] S-negative K-mixed P-pure mice can be used as parents for step five.
[0073] V. Preparation of Mice S-positive, K-mixed, and P-mixed mice were mated with S-negative, K-mixed, and P-pure mice to produce offspring. The S-positive, K-mixed, and P-mixed mice used as parents could be either S-positive, K-mixed, or P-mixed offspring from step one, or S-positive, K-mixed, and P-mixed offspring from step two. The S-negative, K-mixed, and P-pure mice used as parents could be KP mice, or S-negative, K-mixed, and P-pure offspring from step two, three, or four.
[0074] Of the offspring mice, about one-eighth were S-positive, K-positive, and P-pure mice.
[0075] Of the offspring mice, approximately one-eighth were S-negative, K-mixed, and P-pure. S-negative, K-mixed, and P-pure mice can be used in place of KP mice for step one. S-negative, K-mixed, and P-pure mice can be used for step four.
[0076] Of the offspring mice, approximately one-eighth were S-positive, K-negative, and P-pure. These S-positive, K-negative, and P-pure mice can be used for step six.
[0077] Of the offspring mice, approximately one-eighth were S-positive, K-positive, and P-positive.
[0078] VI. Preparation of Mice Mice with S-positive, K-mixed, and P-pure genes were mated with mice with S-positive, K-negative, and P-pure genes to produce offspring. The S-positive, K-mixed, and P-pure parent mice could be any of the offspring obtained in step two, three, or five.
[0079] Of the offspring mice, approximately 3 / 8 were S-positive, K-positive, and P-pure. These mice can replace the S-positive, K-positive, and P-pure mice used in the aforementioned steps as parents.
[0080] Of the offspring mice, approximately one-eighth are S-negative, K-positive, and P-positive mice. These can replace the S-negative, K-positive, and P-positive mice used in the aforementioned steps as parents.
[0081] Of the offspring mice, approximately 3 / 8 were S-positive, K-negative, and P-pure. These mice can replace the S-positive, K-negative, and P-pure mice used in the aforementioned steps as parents.
[0082] Approximately one-eighth of the offspring mice are S-positive, K-mixed, and P-mixed. These mice can replace the S-positive, K-mixed, and P-mixed mice used in the aforementioned steps as parents.
[0083] VII. Methods for identifying mice in steps one through six Ten days after birth, tail tissue was collected from mice, total DNA was extracted, and then PCR identification was performed.
[0084] 1. Identification of K-mixed or K-negative Primer sequences for Kras PCR identification: Mutant upstream primer (SEQ ID NO: 1): 5'-GCAGGTCGAGGGACCTAATA-3'; Wild-type upstream primer (SEQ ID NO: 2): 5'-TGTCTTTCCCCAGCACAGT-3'; Universal downstream primer (SEQ ID NO: 3): 5'-CTGCATAGTACGCTATACCCTGT-3'.
[0085] The target fragment size of the mutant target sequence is 100bp, and the target fragment size of the wild-type target sequence is 250bp.
[0086] Using total DNA as a template, PCR amplification was performed using the three primers described above, followed by agarose gel electrophoresis. If both 100bp and 250bp amplification products were obtained, it was identified as K-heterozygous (K-heterozygous mutant). If a 250bp amplification product was obtained but no 100bp amplification product was obtained, it was identified as K-negative (K-wild-type).
[0087] 2. Identification of pure P and impure P Primer sequences used for Trp53 PCR identification: Upstream primer (SEQ ID NO: 4): 5'-GGTTAAACCCAGCTTGACCA-3'; Downstream primer (SEQ ID NO: 5): 5'-GGAGGCAGAGACAGTTGGAG-3'.
[0088] The target fragment size of the mutant target sequence is 300bp-400bp, and the target size of the wild-type target sequence is 270bp.
[0089] Using total DNA as a template, PCR amplification was performed using the two primers described above, followed by agarose gel electrophoresis. If a 300bp-400bp amplification product was obtained but no 270bp amplification product was obtained, it was determined to be P-pure (P homozygous mutant). If a 300bp-400bp amplification product and a 270bp amplification product were obtained, it was determined to be P-heterozygous (P heterozygous mutant).
[0090] 3. Identifying S-positive and S-negative Primer sequences for Sox9-cre / ERT2 PCR identification: Upstream primer for transgenic organism (SEQ ID NO: 6): 5'-CGGTTTCGTTCTCTGTTTTCC-3'; Transgenic downstream primer (SEQ ID NO: 7): 5'-AGGCAAATTTTGGTGTACGG-3'.
[0091] Internal positive control upstream primer (SEQ ID NO: 8): 5'-AGTGGCCTCTTCCAGAAATG-3'; Internal positive control downstream primer (SEQ ID NO: 9): 5'-TGCGACTGTGTCTGATTTCC-3'.
[0092] The target fragment size of the transgenic target sequence is 290bp-310bp, while the target fragment size of the internal positive control is 521bp.
[0093] Using total DNA as a template, PCR amplification was performed using both the transgenic primer pair (composed of the aforementioned transgenic upstream and downstream primers) and the positive control primer pair (composed of the aforementioned internal positive control upstream and downstream primers), followed by agarose gel electrophoresis. If PCR amplification using the transgenic primer pair yielded a 290-310 bp amplification product and PCR amplification using the positive control primer pair yielded a 521 bp amplification product, the result was considered S-positive. If PCR amplification using the transgenic primer pair did not yield a 290-310 bp amplification product but PCR amplification using the positive control primer pair yielded a 521 bp amplification product, the result was considered S-negative.
[0094] The S-positive, K-positive, and P-pure mice obtained in this embodiment are KPPS mice.
[0095] Example 2: Preparation of a mouse model of intraductal papillary mucinous tumor of the pancreas Test mice: 8-week-old KPPS mice (prepared in step three of Example 1).
[0096] I. Tamoxifen-induced Test mice were administered the drug for 6 consecutive days, with tamoxifen solution injected intraperitoneally once daily (the dosage of tamoxifen was 100 mg / kg body weight). The day of the 6th administration was designated as day 0, and subsequent days were counted consecutively.
[0097] II. Histopathological evaluation of pancreas Mice were sampled on days 28, 56, 84, 112, 140, and 168. Pancreatic tissue was harvested after dissection and prepared into sections, which were then stained with Hematoxylin and eosin (H&E). Two pathologists analyzed the tissue sections after H&E staining. Characteristics of LG-IPMN: Branching papillary structures within the pancreatic ducts, covered with mildly atypical epithelial cells, accompanied by intracellular / extracellular mucus accumulation. Characteristics of HG-IPMN: More numerous and complex papillary structures, significant cellular atypia, increased mitotic figures, increased nuclear-cytoplasmic ratio, loss of nuclear polarity, and no signs of invasive carcinoma. Characteristics of IPMN-IC: Abnormally structured small glands are visible in the duct wall, with distorted glandular structure and an increased nuclear-cytoplasmic ratio.
[0098] The results are shown in Table 1. LG-IPMN was observed in pancreatic tissue sections from KPPS mice after 4 weeks of tamoxifen treatment, and IPMN-IC was observed in KPPS mice after 12 weeks of tamoxifen treatment. HG-IPMN and IPMN-IC were also observed in KPPS mice. Exemplary sections of LG-IPMN, HG-IPMN, and IPMN-IC are shown in Table 1. Figure 1 .
[0099] Table 1. Number and percentage of mice at each sampling time and at each disease stage.
[0100] Example 3, Survival Analysis Test mice: 46 eight-week-old KPPS mice (prepared in step three of Example 1) or 25 KPPC mice (purchased).
[0101] Test mice were administered the drug for 6 consecutive days, with tamoxifen solution injected intraperitoneally once daily (the dosage of tamoxifen was 100 mg / kg body weight). The day of the 6th administration was designated as day 0, and subsequent days were counted consecutively.
[0102] Starting from day 1, every 7 days is considered a week, and the survival rate of mice is recorded weekly to create a survival curve.
[0103] See results Figure 2 The median survival of KPPS mice was 20 weeks after tamoxifen injection (n=46). The median survival of KPPC mice was 13 weeks after tamoxifen injection (n=25). There was a significant difference in median survival between the two mouse types (P<0.0001), with KPPS mice having a significantly longer median survival than KPPC mice.
[0104] Example 4: Obtaining the KPPS cell line and using it for mouse modeling. I. KPPS Cell Construction 1. Aseptically collect pancreas samples from KPPS mice in the IPMN-IC stage (prepared in Example 2), isolate tumors, rinse the tumors in PBS buffer to remove excess blood, cut off non-tumor tissues such as blood vessels on the tumors, and then transfer the tumors to a new 6cm diameter culture dish and cut them into minced meat with sterile scissors.
[0105] 2. After completing step 1, take the culture dish, add 3 mL of 0.25% trypsin solution, and digest at 37°C for 15-30 minutes (the following morphology is observed under a microscope: cells are released into cell clumps, and the edges of the cell clumps become transparent).
[0106] 3. After completing step 2, take the culture dish, add 6 mL of DMEM complete culture medium to terminate digestion, then filter it through a cell sieve with a pore size of 70 μm and collect the filtrate.
[0107] 4. Take the filtrate obtained in step 3, centrifuge at 800g for 10min, discard the supernatant, and resuspend the cell pellet in 5mL of DMEM complete culture medium to obtain a cell suspension.
[0108] 5. Take a 6-well plate, seed it with the cell suspension obtained in step 4, and culture until the confluence reaches 90% (replace the culture medium every 2-3 days). The cells in this step are P0 generation cells.
[0109] 6. After completing step 5, discard the supernatant, add 0.25% trypsin solution, digest for 2-3 minutes, and then passage at a 1:3 ratio. After 10 passages, if the cells exhibit uniform morphology and a relatively stable growth rate, the cell line is considered successfully established.
[0110] It was named KPPS cells (also known as the KPPS cell line).
[0111] II. Cell Immunofluorescence Staining 1. Place a standard clean glass slide in a 6-well plate, and seed each well with 2 × 10⁻⁶ slides. 5 KPPS cells were cultured overnight.
[0112] 2. After completing step 1, discard the supernatant and wash twice with PBS buffer.
[0113] 3. After completing step 2, add 1 mL of fixative (4% paraformaldehyde solution) to each well and fix at room temperature for 20 minutes.
[0114] 4. After completing step 3, discard the fixative and wash three times with PBS buffer (5 minutes each time, with gentle shaking).
[0115] 5. After completing step 4, add 0.6 mL of PBS buffer containing 0.5% Triton X-100 to each well for cell permeation, incubate at room temperature for 20 minutes, then discard the liquid and wash three times with PBS wash buffer.
[0116] 6. After completing step 5, add 0.6 mL of blocking solution (i.e., goat serum) to each well, incubate for 30 minutes, and then discard the blocking solution.
[0117] 7. After completing step 6, add 0.5 mL of primary antibody working solution to each well and incubate overnight at 4°C with shaking.
[0118] Primary antibody (recombinant antipan cytokeratin antibody): Abcam, product catalog number ab7753.
[0119] 8. After completing step 7, discard the primary antibody working solution and wash three times with PBS buffer.
[0120] 9. After completing step 8, add 0.5 mL of secondary antibody working solution to each well, incubate at room temperature in the dark with shaking for 60 minutes, and shake gently.
[0121] Secondary antibody (goat anti-mouse IgG H&L, Alexa Fluor® 488): Abcam, catalog number ab150113.
[0122] 10. After completing step 9, discard the secondary antibody working solution and wash three times with PBS buffer.
[0123] 11. After completing step 10, add 0.2 mL of DAPI solution to each well and incubate in the dark for 5 minutes.
[0124] 12. After completing step 11, discard the DAPI solution, wash the slide four times with PBS buffer (5 minutes each time), then blot off any excess liquid with filter paper, add anti-fading mounting solution, and gently cover the cells with the coverslip, ensuring there are no air bubbles and that the cells are in contact with the mounting solution. Finally, image the slide using a confocal microscope.
[0125] See exemplary imaging photographs Figure 3 Immunofluorescence staining confirmed that KPPS cells had an epithelial phenotype (PanCK+) and exhibited significant mitotic activity.
[0126] III. Cell Proliferation Experiment 1. Collect KPPS cells in the logarithmic growth phase, digest them with 0.25% trypsin solution, then centrifuge at 1000 rpm for 1 minute, collect the cell pellet, wash the cell pellet with PBS buffer, and then resuspend the cell pellet in DMEM complete medium to obtain a cell suspension. Count the cells using trypan blue staining.
[0127] 2. In a 64-well plate, seed 1 mL of cell suspension (containing 3000 cells) into each well, then add 0.2 mL of DMEM complete medium to each well and incubate for 1 day.
[0128] 3. After completing step 2, continue culturing until the cell density reaches over 90%. During the culturing process, add 0.05 mL of fixative (10% trichloroacetic acid solution) every two days.
[0129] 4. After completing step 3, continue culturing for one day, discard the liquid in the wells, wash the cells twice with PBS, and then air dry for 30 minutes.
[0130] 5. After completing step 4, add 0.05 mL of SRB (Sorphrolidine B) dye solution to each well, incubate for 30 minutes, then wash twice with 1% acetic acid and air dry.
[0131] 6. After completing step 5, add 0.05 mL of Tris alkaline solution (containing 10 mM 2-amino-2-hydroxymethylpropane-1,3-diol, pH=10.5) to each well to resuspend the cells, and then use an ELISA reader to measure the absorbance at a wavelength of 564 nm.
[0132] Cell proliferation experiments showed that KPPS cells grew vigorously, with a doubling time of approximately 31 hours.
[0133] IV. Establishment of a mouse model of subcutaneous tumor KPPS cells were subcutaneously injected into the unilateral scapular region of 12 mice (half male and half female) at a dose of 5 × 10⁶ cells per mouse. 6 Individual cells. Continuous monitoring after injection revealed that mice could grow subcutaneous tumors, and by day 14 post-injection, the maximum diameter of most tumors had exceeded 10 mm.
[0134] The present invention has been described in detail above. For those skilled in the art, the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. Although specific embodiments have been given, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein. Some of the essential features can be applied within the scope of the following appended claims.
Claims
1. A method for constructing genetically engineered mice for preparing a model mouse of intraductal papillary mucinous tumor of the pancreas, characterized in that: The genetically engineered mice used to create a model of intraductal papillary mucinous tumors of the pancreas were named KPPS mice. The method includes the following steps: hybridizing S-positive mice and K-P pure mice as parents to obtain KPPS mice; The S-positive mouse is a transgenic mouse carrying Sox9-CreER; the Sox9-CreER is a DNA molecule, which has a promoter and a Cre recombinase gene transcribed by the promoter sequentially from upstream to downstream; the promoter is a pancreatic duct cell-specific promoter; the Cre recombinase gene encodes Cre recombinase; The K-P pure mice carry loxP-Trp53-loxP in both pairs of homologous chromosomes 11, and Promoter-LSL-Kras in one of their chromosomes 6. G12D ; The loxP-Trp53-loxP is obtained by modifying the Trp53 gene located on chromosome 11. The modification refers to inserting two loxP sites in the Trp53 gene with the same direction, and the two loxP sites are inserted at different positions in the Trp53 gene. The loxP site recombination of loxP-Trp53-loxP resulted in the knockout of the Trp53 gene; the loxP site recombination was mediated by the Cre recombinase. The Promoter-LSL-Kras G12D It is obtained by modifying the region from the promoter of the Kras gene on chromosome 6 to the end of the Kras gene; the Promoter-LSL-Kras G12D From upstream to downstream, the sequence consists of the Kras gene promoter, LSL sequence, and Kras gene promoter. G12D Mutant gene; LSL sequence is a DNA fragment with two loxP sites in the same orientation and a termination box located between the two loxP sites; Kras G12D The expression of the mutant gene was blocked by the LSL sequence; the Promoter-LSL-Kras G12D Recombination at the loxP site leads to the expression of Kras, which is blocked by the LSL sequence. G12D The mutant gene is restored to expression; the recombination at the loxP site is mediated by the Cre recombinase. The KPPS mice are S-positive, K-hybrid, and P-pure mice; S-positive, K-hybrid, and P-pure mice mean that they carry the Sox9-CreER, and both pairs of homologous chromosomes 11 carry the loxP-Trp53-loxP, and one chromosome 6 carries the Promoter-LSL-Kras. G12D .
2. A method for preparing a mouse model of intraductal papillary mucinous tumor of the pancreas, comprising the following steps: (1) Construct KPPS mice according to the method of claim 1; (2) The KPPS mice were induced by an inducer to obtain a model mouse of intraductal papillary mucinous tumor of the pancreas.
3. The method as described in claim 2, characterized in that: In step (2), starting from week 4 after the induction is completed, a mouse model of intraductal papillary mucinous tumor of the pancreas in the IPMN stage is obtained.
4. The application of the KPPS mice prepared by the method of claim 1; the application is to prepare a mouse model of intraductal papillary mucinous tumor of the pancreas.
5. The application of the mouse model of intraductal papillary mucinous tumor of the pancreas prepared by the method of claim 2 or 3; wherein the application is as follows (a) or (b) or (c): (a) Presenting the pathological progression during the development of IPMN; (b) To conduct mechanistic studies on the progress of IPMN; (c) Conduct drug screening during the progress of IPMN.
6. A type of tumor cell, which is a tumor cell derived from a mouse model of intraductal papillary mucinous tumor of the pancreas prepared by the method of claim 2 or 3.
7. The tumor cells as described in claim 6, characterized in that: The tumor cells were isolated from pancreatic tumor tissue in mice with the intraductal papillary mucinous tumor model of pancreatic tumor.
8. A tissue or organ, characterized by: The tissue or organ is derived from a tumor in a mouse model of intraductal papillary mucinous tumor of the pancreas prepared by the method of claim 2 or 3.
9. A tissue or organ, characterized by: The tissue or organ is derived from a tumor in a tumor-bearing mouse; the tumor-bearing mouse is a mouse in which tumor cells of claim 6 or 7 are inoculated into a starting mouse and a tumor develops.
Citation Information
Patent Citations
Establishment method of intraductal papillary mucinous neoplasm model
CN110278913A
CLDN18.2-knockout mouse model with pancreas specificity as well as construction method and application of CLDN18.2-knockout mouse model
CN114634931A
